MA-LOADSPRING-SOLUTIONS
14.9.2022 19:31:33 CEST | Business Wire | Press release
LoadSpring Solutions, Inc., the enterprise market leader in project platform solutions, has accepted a strategic majority interest investment from Blattner Technologies. Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
LoadSpring’s partnership with Blattner Technologies aligns with our industry focus on digital transformation and advancing data usability, analytics, machine learning, and artificial intelligence. Blattner’s focus on AI and predictive technologies will help lead to our customers' next generation of advancement.
“Today’s investment announcement will enable LoadSpring to rapidly expand its vision of driving the project controls industry to a future where it aspires to be. This new partnership, including the additional board membership, will accelerate our platform development and AI/analytics technology innovation to enable faster geographic and industry expansion, truly unlocking LoadSpring’s potential. Together, our expertise in providing global cloud solutions for project-based organizations and our new partner's expertise in building companies will provide next-generation solutions for our customers,” states Eric Leighton, President and CEO of LoadSpring Solutions, Inc.
Blattner Technologies’ CEO Russ Blattner says, “LoadSpring has the resources and tools to complement the list of companies Blattner Technologies is acquiring in our mission to build a predictive transformation model that takes our customers from the basics of data management and analytics to operationalizing AI/ML and true predictive analytics throughout an organization.”
LoadSpring’s global office locations and executive management teams will remain in place, with Eric Leighton continuing in his leadership role as President and CEO. Blattner Technologies representatives Russ Blattner and John Leschorn, along with Terrance Berland, co-founder of Unicorn & Lion, LLC, will join the LoadSpring Board of Directors, providing operational and technology vision to drive customer solutions into the future.
“This investment combines secure technology infrastructure and next-generation tools and analytics to create a truly distinctive solution offering for customers. This is an industry trend that will continue as organizations better understand the power of controlling and mining their data and look for partners that can bring them complete solutions, not just pieces,” says Terrance Berland, a member of the Forbes Technology Council.
About Blattner Technologies
Nashville, TN Blattner Technologies – Building on a 115-year legacy of innovation by the Blattner family of companies, Blattner Technologies is on a mission to be the leading provider of Predictive TransformationTM services and tools in the data analytics, artificial intelligence, and machine learning industries.
About LoadSpring
Founded in 1999, LoadSpring is a global project management provider obsessed with offering advanced managed cloud services. LoadSpring delivers expert project management and control solutions, fast data and business intelligence access, and hundreds of best-of-breed project-based applications. Data safety is assured through SOC 2 Type II security certification, providing an impenetrable cloud environment. LoadSpring customers and partners get higher productivity and ROI through our proprietary project platform while reducing the burden on their IT departments.
For more information, contact Stacey Witt at switt@loadspring.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom